Douglas A. Holt, MD, FACP, IDSA

Biographical Sketch

Douglas A. Holt, MD, FACP, is the Andor Szentivanyi Professor of Medicine and Director of the Division of Infectious Disease & International Medicine at the Morsani College of Medicine at the University of South Florida. He has also been the Director of the Florida Department of Health - Hillsborough County (HCHD) since 1996.  Dr. Holt earned his medical degree from the University of South Alabama and completed his residency in Internal Medicine and his fellowship in Infectious Disease at the University of South Florida College of Medicine.

Dr. Holt has played an active role in many Florida Department of Health workgroups and committees, including the Fiscal Management Advisory Council, Fetal Infant Mortality Review Board, the Secretary’s Roundtable, and the Florida Association of County Health Officers.  In 2001 to 2002, Dr. Holt was the Acting Deputy State Health Officer and played a crucial part in directing the anthrax investigation in Lantana, Florida.  He served in this capacity again in 2011.  In 2012, Dr. Holt was presented with the Distinguished Service to the State of Florida award from the Executive Office of Governor, Rick Scott.

Dr. Holt has been successful in the integration of public health services and those of the university to create a seamless system that enhances patient care.  Through his efforts, the Florida Department of Health and USF have cooperative agreements that provide professional medical services from university professors who serve in the critical public health positions of communicable disease and HIV research.  Since joining the USF faculty in 1989, Dr. Holt has also pioneered collaborative work with the burn, solid organ transplant, BMT and trauma units at Tampa General Hospital (TGH) and has been a charter member of the TGH Cardiac Transplant and Liver Transplant Teams.  

One of Dr. Holt’s passions is fostering research.  During his tenure as Professor and Health Department Director, literally hundreds of research studies have been completed and grants submitted.  He has been Principal Investigator (PI) or co-PI on 57 research protocols, secured a $1 million HUD grant for a research facility build-out and authored 21 peer-reviewed publications.

Dr. Holt is an active member of many national, state and local organizations such as the American College of Physicians, Infectious Disease Society of America, Hillsborough County Medical Association, American Medical Association, the Florida Medical Association, Florida Infectious Disease Society, and The National Association of County & City Health Officials.  He is also a graduate of the National Public Health Leadership Institute Class 1.

Dr. Holt is acclaimed as an “Outstanding Teacher” by students, residents and fellows.  He has been very active with the Infectious Disease Fellowship program and helped start the first HIV ward in Florida.  He has been recognized twice as “Best Teacher” by the Fellows.

Areas of Expertise

• Pandemic Preparedness
• Public Health Policy
• Influenza

Current Research

Wills T, Holt DA. A Multicenter, Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety of Maraviroc in Combination with Other Antiretroviral Agents in HIV-1Infected Subjects Co-Infected with Hepatitis C and/or Hepatitis B Virus [Protocol: A4001098], 2011 - Present

Montero J, Holt DA. A Multicenter, Randomized, Double Blind, Comparative Trial of Maraviroc + Darunavir/Ritonavir versus Emtricitabine/Tenofovir +Darunavir/Ritonavir for the Treatment of Antiretroviral-Naïve HIV Infected Patients with CCR5 Tropic HIV-1 [Protocol: A4001095], 2011 - Present

Emmanuel P, Holt DA. IMPAACT 1077HS - HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere), 2010 - Present

Casanas B, Holt DA. A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virilogically-Suppressed, HIV-1 Infected Patients [GS-US-264-0106], 2011 - Present

Wills T, Holt DA. A Phase 3, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir versus Ritonavir-boosted Atazanavir. Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. [Protocol: GS-US-216-0114 (Gilead Sciences)], 2010 - Present

Wills T, Holt DA. Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emrticitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Ritonavir-Booster Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults [Protocol: GS-US-236-0103 (Gilead Sciences)], 2010 - Present

Wills T, Holt DA. A Phse 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitavine/Tenofovir Disoproxil Fumarate/GS-9350 versus Favirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults [Protocol: GS-US-236-0102 (Gilead Sciences)], 2010 - Present

Publications

Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott BA, Nauert GM, Soety E, Sossi V, Holt DA, Sanberg PR, Stoessl AJ, Freeman TB. Bilateral human fetal striatal transplantation in Huntington’s disease, Neurology 58: 687-695, 2002

Ganguly R, Holt DA, Sinnott JT. Exposure of Medical Students to Body Fluids, The Journal of American College Health, 47:207, 1999

Freeman TB, Olanow CW, Hauser RA, Kordower JH, Holt DA, Borlongan CV, Sanberg PR. Human Fetal Tissue Transplantation, Neurosurgical Treatment of Movement Disorders, The American Association of Neurological Surgeons Chapter 13, 177-192, 1998

Nadler JP, Oehler RL, Holt DA. Update of Antiretroviral Therapy For HIV Infection, Infections in Medicine 15:113,1998

Holt DA, Nauert MG, Othberg AI, Randall TS, Willing AE, Widen RH, Hauser RA, Sanberg PR, Olanow CW, Freeman TB. Infectious Issues In Fetal Neural Transplantation, Cell Transplantation, 6:553, 1997

Holt DA, Larkin JA. Continuing Issues in Ventilator-Associated Pneumonia. Infections in Medicine, 12:12, 1995

Freeman TB, Olanow CW, Hauser RA, Nauert M, Smith DA, Borlongan CV, Sanberg PR, Holt DA, Kordower JH, Vingerhoets FJG, Snow BJ, Calne D, Gauger BS. Bilateral Fetal Nigral Transplantation into the Postcommissural Putamen in Parkinson's Disease, Annals of Neurology, 38:379, 1995

Abstracts

Holt DA, Co-Investigator. Gilead (GS-US-264-0106). A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-booested Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/ Tenofovir Disoproxil Fumarate 9FTC/RPV/TDF) Fixed-dose Regimen in Virologically-Suppressed, HIV-1 Infected Patients

Holt DR, Co-Investigator. Pfizer (A4001098) Multicenter, Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety of Maraviroc in Combination with Other Antiretroviral Agents in HIV-1 Infected Subjects Co-Infected with Hepatitis C and/or Hepatitis B Virus

Holt DA, Co-Investigator. NICHD and NIAID (IMPAACT 1077HS) HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)

Holt DA, Co-Investigator. Cepheid (MRSA 123) Clinical Evaluation of the Xpert™ SA Nasal-CLIA Waived Assay for Nasal Swabs

Holt DA, Co-Investigator. A Phase IIIb, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compares with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults (Gilead GS-US-264-0110 - February 2011]

Holt DA, Co-Investigator. A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically-Suppressed, HIV-1 Infected Patients [Gilead GS-US-264-0106 February 2011]

Holt DA, Co-Investigator. An Open-label Trial with TMC278 25 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in HIV-1 Infected Subjects, Who Participated in TMC278 Clinical Trials [Protocol: TMC278-TiDP6-C222 - January 2011]

Search Google Scholar for Publications by Dr. Holt

Dr. Holt's CV